1. Comparison of different intravenous iron preparations in terms of total oxidant and total antioxidant status, single center data

   • Ferda Can
   • Keziban Naz Yılmaz
   • Tekin Güney

   Original Article 11 July 2023 Pages: 2645 - 2650

2. Association between anemia and depression: results from NHANES 2005–2018 and mendelian randomization analyses

   • Yashan Wang
   • Dingjie Guo
   • Xin Liu

   Original Article 22 July 2023 Pages: 2651 - 2658

   

3. Recent national trends in outcomes and economic disparities among adult sickle cell disease-related admissions

   • Vaishali Deenadayalan
   • Rafaella Litvin
   • Maryam Zia

   Original Article 31 July 2023 Pages: 2659 - 2669

   

4. Clinical features and prognostic risk prediction of adult hemophagocytic lymphohistiocytosis: a 9-year retrospective study

   • Qunxiang Qiu
   • Dan Li
   • Jianchuan Deng

   Original Article 18 July 2023 Pages: 2671 - 2682

   

5. Genomic and computational analysis of four novel variants of MPL gene in Congenital Amegakaryocytic Thrombocytopenia

   • Anjali Shah
   • Chandan Kumar
   • Babu Rao Vundinti

   Original Article 13 July 2023 Pages: 2683 - 2693

   

6. Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia

   • Wenbing Duan
   • Sen Yang
   • Qian Jiang

   Original Article 12 August 2023 Pages: 2695 - 2705

   

7. Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era

   • Feiyang Qi
   • Mei Bao
   • Qian Jiang

   Original Article 14 August 2023 Pages: 2707 - 2716

8. Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension

   • Olga Mulas
   • Brunella Mola
   • Giovanni Caocci

   Original Article Open access 21 August 2023 Pages: 2717 - 2723

   

9. A novel germline hyperactivating JAK2 mutation L604F

   • Lukáš Dvořáček
   • Jana Marková
   • Jiří Schwarz

   Original Article Open access 28 August 2023 Pages: 2725 - 2734

   

10. Genetic mutations and leukapheresis in acute myeloid leukemia: is there a link?

    • Andrea Corbingi
    • Rossana Putzulu
    • Nicola Piccirillo

    Original Article 17 August 2023 Pages: 2735 - 2740

    

11. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

    • Susanne Isfort
    • Kirsi Manz
    • for the German CML study group

    Original Article Open access 18 August 2023 Pages: 2741 - 2752

    

12. Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry

    • Ethan A. Burns
    • Justin J. Wilson
    • Sai Ravi Pingali

    Original Article 08 July 2023 Pages: 2753 - 2763

    

13. A prediction model for severe hematological toxicity of BTK inhibitors

    • Dan Jiang
    • Zaiwei Song
    • Rongsheng Zhao

    Original Article 25 July 2023 Pages: 2765 - 2777

    

14. Role of body composition and metabolic parameters extracted from baseline ¹⁸F-FDG PET/CT in patients with diffuse large B-cell lymphoma

    • Yang Chen
    • Zhijian Chen
    • Lei Jiang

    Original Article 02 August 2023 Pages: 2779 - 2789

    

15. The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis

    • Luca Fischer
    • Linmiao Jiang
    • on behalf of the German Lymphoma Alliance (GLA) and the German Low-Grade Lymphoma Study Group (GLSG)

    Original Article Open access 08 August 2023 Pages: 2791 - 2801

    

16. Extranodal natural killer/T-cell lymphoma with hepatosplenic involvement: a retrospective study of a consecutive 14-year case series

    • Yue-Hua Zhang
    • Zheng Li
    • Li-Min Gao

    Original Article 12 July 2023 Pages: 2803 - 2813

    

17. Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry

    • Lilian Goveia
    • Nelson Castro
    • Irene Biasoli

    Original Article 21 July 2023 Pages: 2815 - 2822

    

18. Hand grip strength, short physical performance battery, and gait speed: key tools for function in Non-Hodgkin Lymphoma

    • Agurne García-Baztán
    • Mari Cruz Viguria-Alegria
    • Julio Oteiza-Olaso

    Original Article 11 August 2023 Pages: 2823 - 2834

    

19. Treating relapsed B cell-precursor ALL in children with a setting-adapted mitoxantrone-based intensive chemotherapy protocol (TMH rALL-18 PROTOCOL) — experience from Tata Memorial Hospital, India

    • Nirmalya Roy Moulik
    • Swaminathan Keerthivasagam
    • Shripad Banavali

    Original Article 21 July 2023 Pages: 2835 - 2844

    

20. Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma

    • Chen Gong
    • Jiazhuo Wu
    • Mingzhi Zhang

    Original Article 27 July 2023 Pages: 2845 - 2855

    

21. Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease

    • Qing He
    • Xuelin Dou
    • Jin Lu

    Original Article 12 July 2023 Pages: 2857 - 2864

    

22. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study

    • Jiapei Liu
    • Zhiping Fan
    • Hua Jin

    Original Article 20 July 2023 Pages: 2865 - 2877

    

23. Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy

    • Hiroaki Araie
    • Yasuyuki Arai
    • for the Adult Acute Myeloid Leukemia Working Group of the Japanese Society for Transplantation and Cellular Therapy

    Original Article Open access 21 July 2023 Pages: 2879 - 2893

    

24. Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial

    • Naoki Kurita
    • Hidekazu Nishikii
    • Shigeru Chiba

    Original Article 17 August 2023 Pages: 2895 - 2902

    

25. Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML

    • Anjali Cremer
    • Julius C. Enssle
    • Gesine Bug

    Original Article Open access 08 August 2023 Pages: 2903 - 2908

    

26. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan

    • Tomoki Iemura
    • Tadakazu Kondo
    • Akifumi Takaori-Kondo

    Original Article 13 April 2023 Pages: 2909 - 2922

    

27. Association between ABO blood groups and SARS-CoV-2 infection in blood donors of Puglia region

    • Alessia Sticchi Damiani
    • Antonella Zizza
    • The Seroprevalence COVID Blood Donors Study Group

    Original Article Open access 13 July 2023 Pages: 2923 - 2931

28. Lack of surgical resection is associated with increased early mortality in hematological patients complicated with rhino-orbital-cerebral mucormycosis

    • Xinyue Chen
    • Juan Xiao
    • Weiwei Tian

    Original Article 08 July 2023 Pages: 2933 - 2942

    

29. More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma

    • Mengru Tian
    • Xinyue Liang
    • Fengyan Jin

    Letter to the Editor 12 July 2023 Pages: 2943 - 2945

    

30. Inherited macrothrombocytopenia due to a novel splice donor site mutation in ITGB3

    • Yukiko Komeno
    • Toru Uchiyama
    • Akira Ishiguro

    Letter to the Editor 29 July 2023 Pages: 2947 - 2949

    

31. Successful treatment of systemic mastocytosis with acute myeloid leukemia: a case report

    • Minran Zhou
    • Guangcai Zhong
    • Chunyan Chen

    Letter to the Editor 11 July 2023 Pages: 2951 - 2953

    

32. Successful treatment of systemic EBV-positive T-cell lymphoma of childhood using the ruxolitinib combined with L-DEP regimen chemotherapy followed by haploidentical allogeneic hematopoietic stem cell transplantation

    • Jian Li
    • Chunyan Cao
    • Yongjun Fang

    Letter to the Editor 25 July 2023 Pages: 2955 - 2957

    

33. Mass cytometry analysis of B-cell populations in extranodal marginal-zone lymphoma of mucosa-associated lymphoid tissue of the lung

    • Toyoshi Yanagihara
    • Kentaro Hata
    • Isamu Okamoto

    Letter to the Editor 31 July 2023 Pages: 2959 - 2961

    

34. Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?

    • Alice Di Rocco
    • Martina Di Palma
    • Maurizio Martelli

    Letter to the Editor 19 July 2023 Pages: 2963 - 2964

35. Real-life experience with luspatercept in transfusion-dependent β-thalassemia

    • Daniela Roccotelli
    • Domenica Grande
    • Pellegrino Musto

    Letter to the Editor 27 July 2023 Pages: 2965 - 2967

    

36. One disease, two faces: clonally-related AML and MPDCP with skin involvement

    • Giovanni Martino
    • Gaetano Cimino
    • Maria Paola Martelli

    Letter to the Editor 22 July 2023 Pages: 2969 - 2971

    

37. Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases

    • Yupeng Wang
    • Zi Wang
    • Daobin Zhou

    Letter to the Editor 31 July 2023 Pages: 2973 - 2975

    

38. A synchronous therapy with daratumumab and enzymatic replacement therapy (ERT) in a patient with Gaucher disease and multiple myeloma

    • A. Rago
    • G. Palumbo
    • T. Caravita di Toritto

    Letter to the Editor 11 July 2023 Pages: 2977 - 2978